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Aims Wehypothesized that carvedilol caneffectively suppress autonomicnerveactivity (ANA) in ambulatorydogsduring sinus
rhythm and atrial fibrillation (AF), and that carvedilol withdrawal can lead to rebound elevation of ANA. Carvedilol is
known to block pre-junctional b2-adrenoceptor responsible for norepinephrine release.
Methods
and results
We implanted radiotransmitters to record stellate ganglionnerve activity (SGNA), vagal nerve activity (VNA), and superior
left ganglionatedplexinerveactivity (SLGPNA) in12ambulatorydogs.Carvedilol (12.5 mgorally twiceaday)wasgiven for7
daysduring sinus rhythm(n ¼ 8).Fourof theeightdogsandanadditional fourdogswerepaced intopersistentAF.Carvedilol
reduced heart rate [from103 b.p.m. (95% confidence interval (CI), 100–105) to 100 b.p.m. (95%CI, 98–102), P ¼ 0.044],
suppressed integratednerveactivities (Int-NAs, SGNAby17%,VNAby19%,andSLGPNAby12%; allP, 0.05vs. thebase-
line), and significantly reduced the incidence (from8+6to3+3episodes/day,P, 0.05) and totalduration (from68+64
to 16+21 s/day, P, 0.05) of paroxysmal atrial tachycardia (PAT). Following the development of persistent AF, carvedilol
loading was associated with AF termination in three dogs. In the remaining five dogs, Int-NAs were not significantly sup-
pressed by carvedilol, but SGNA significantly increased by 16% after carvedilol withdrawal (P, 0.001).
Conclusion Carvedilol suppresses ANA and PAT in ambulatory dogs during sinus rhythm.
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Introduction
b-Blockers are commonly used in the treatment of heart failure and
cardiac arrhythmias. Large clinical trials have documented the effi-
cacy of b-blockers in improving the outcomes of heart failure.1,2
However, not all b-blockers are equally effective in these regards.
The Carvedilol Or Metoprolol European Trial (COMET) compared
the effects of carvedilol and metoprolol on clinical outcomes in
patients with chronic heart failure.3 The investigators found that car-
vedilol is more effective than metoprolol in prolonging survival. Car-
vedilol is alsomoreeffective thanplacebo in reducing the incidenceof
atrial fibrillation (AF) and atrial flutter after myocardial infarction.4
Because carvedilol is a non-selective b-blocker that blocks a1-,
b1-, and,b2-adrenergic receptors, whereasmetoprolol is a selective
b1-adrenegic blocker, it is possible that the additional post-junctional
blocking effects of carvedilol explain its superior clinical efficacy over
metoprolol. However, on further analyses of the COMET, Bristow
et al.5 concluded that post-junctional adrenoceptor blockade, that
is, in addition to b1-receptor antagonism will likely produce only
minimal or no incremental benefit in chronic heart failure. An alter-
native explanation of the COMET results is that carvedilol, but not
metoprolol, blocks pre-junctionalb2-adrenergic receptors (facilitat-
ing norepinephrine release) and thereby reduce cardiac sympathetic
outflow.6 The latter hypothesis was supported by a clinical study that
showed carvedilol, but notmetoprolol, reduces systemic and cardiac
norepinephrine spillover, an indirect measure of norepinephrine
release.7 However, no study has directly documented the effects
of carvedilol on cardiac sympathetic nerve activity in ambulatory
animals. We have developed a method to simultaneously measure
stellate ganglion nerve activity (SGNA), vagal nerve activity (VNA),
and superior left ganglionated plexi nerve activity (SLGPNA) in am-
bulatory dogs at baseline and during pacing-induced AF.8 The
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purpose of the present study was to test the hypothesis that carvedi-
lol can effectively suppress autonomic nerve activity (ANA) in ambu-
latory dogs during sinus rhythm and pacing-induced AF, and that
carvedilol withdrawal can lead to rebound elevation of ANA. The
results of this study may be helpful in explaining the beneficial
effects of carvedilol in the management of patients with heart
failure and cardiac arrhythmias.
Methods
The animal research protocol was approved by the Institutional Animal
Care and Use Committee of the Indiana University School of Medicine;
the Methodist Research Institute, Indianapolis, USA; and the Seoul Na-
tional University Hospital, Seoul, Republic of Korea. The protocol con-
forms to the best practices as defined by the Guide for the Care and
Use of Laboratory Animals.
Cardiac autonomic nerve recordings in an
ambulatory canine model
Twelve mongrel dogs (24+5 kg, all male) were used for chronic auto-
nomic nerve recordings. Nerve recording protocols were described in
detail elsewhere.8 Briefly, a Data Sciences International radiotransmitter
(D70-EEE) was used to record three ANAs, including left SGNA, left
VNA from the superior cardiac branch of the left thoracic vagus nerve,
and SLGPNA from the superior left ganglionated plexi located
between the left superior pulmonary vein and left atrium (LA). Pacing
lead for rapid atrial pacing was implanted at the bottom of the left atrial
appendage and connected with a Kappa pacemaker (Medtronic) or a
CurrentDRpacemaker (St JudeMedical). After 2weeks of recovery, car-
vedilol loading test (12.5 mg orally twice a day) was performedwhile the
dogs were in sinus rhythm (phase 1 study, n ¼ 8). Three ANAs were
recorded before, during, and after carvedilol withdrawal (Figure 1).
Rapid atrial pacing (640 b.p.m. for Medtronic pacemaker or 600 b.p.m.
for St Jude Medical pacemaker) was performed continuously for 6 days
followed by 1 day of post-pacing recording. Rapid atrial pacing was
restarted if AF did not sustain for .48 h. The total pacing duration pre-
ceding the induction of persistent AF (.48 h) was 5+3 weeks. Four
dogs did not develop persistent AF after 8–10 weeks of pacing. There-
fore, eight of the eight dogs were used to study the effect of carvedilol
during sinus rhythm, whereas only four dogs were available for the
study of carvedilol in persistent AF. To bolster the number of dogs in
the persistent AF group, we added four dogs that developed persistent
AF after rapid atrial pacing. In these latter four dogs, the effects of carve-
dilolwere studiedonly duringpersistentAF.All eight dogs thatdeveloped
persistentAFwereobserved for an additional 7 days, and all of themwere
found to be in AF throughout this additional 7-day observational period.
After documenting thepresenceofAF for.9days in all thedogs,weper-
formed a second carvedilol loading test (phase 2, N ¼ 8). Stellate gan-
glion nerve activity, VNA, and SLGPNA were recorded before, during,
and after carvedilol withdrawal. During carvedilol loading, three of the
eight dogs converted spontaneously from AF to sinus rhythm. The
remaining five dogs were in persistent AF before, during, and after carve-
dilol therapy.
Data analyses
A three-fold increase in amplitude over baseline noisewas considered
an indication of nerve activity.8We used custom-designed software to
calculate the integrated nerve activities (Int-NAs) relative to carvedi-
lol loading. Stellate ganglion nerve activity, VNA, and SLGPNA were
high-pass filtered at 100 Hz. The filtered signals were rectified, inte-
grated with a 100 ms time constant, and summed at 3 s segments
over 24 h recordings to quantify the Int-NAs. The 24 h nerve activities
of each dog were averaged before, during, and after carvedilol loading
and compared. We also counted the number of paroxysmal atrial
tachycardia (PAT) episodes in the phase 1 study, defined as an abrupt
(.50 b.p.m./s) increase in the atrial rate to .200 b.p.m. that persisted
for at least 5 s.9 We integrated the nerve activity at 1 min intervals to
obtain 1440points over a 24 hperiod.We then constructedplots of inte-
grated SGNA vs. integrated VNA and integrated VNA vs. integrated
SLGPNA, similar to a method that described elsewhere.10,11 Because
rapid atrial activation during persistent AF may significantly contaminate
the SLGPNA recording, we did not analyse the SLGPNA recording
during persistent AF.
Statistical analysis
Datawere presented as mean values and 95% confidence intervals (CIs).
Repeated-measure analyses of variance or mixed analysis were used to
compare the Int-NAs, correlationcoefficients, and the incidenceanddur-
ationof PATbefore, during, and after carvedilol withdrawal. Pearson cor-
relationcoefficientswereused to analyse the associationsbetweennerve
activities. A P ≤ 0.05 was considered statistically significant.
Results
Carvedilol suppresses heart rate and nerve
activities in sinus rhythm
Heart rate decreased during carvedilol loading [from 102.8 b.p.m.
(95% CI, 100.4–105.2) to 100.3 b.p.m. (95% CI, 98.4–102.1)], P ¼
0.044). After carvedilol withdrawal, a further significant decrease in
heart rate was observed compared with values recorded at baseline
and during carvedilol [94.4 b.p.m. (95% CI, 92.5–96.4), P, 0.001
compared with baseline, P, 0.001 compared with carvedilol
loading period, Figure 1B]. We analysed the hourly change in heart
rate at baseline, during carvedilol loading, and after carvedilol with-
drawal. Before carvedilol loading, there was a morning surge of
heart rate starting at 6 AM. This circadian variation was attenuated
after carvedilol loading and withdrawal (Figure 1C). Integrated nerve
activities were suppressed during carvedilol loading in sinus
rhythm, resulting in reduction in SGNA by 17% [from 2.4 mV/s
(95% CI, 2.2–2.6) to 2.0 mV/s (95% CI, 1.9–2.2), P, 0.001], VNA
What’s new?
† Carvedilol effectively suppressed vagal nerve activity (VNA)
and superior left ganglionated plexi nerve activity (SLGPNA)
in addition to stellate ganglion nerve activity (SGNA) in the
basal state.
† The incidence and duration of paroxysmal atrial tachyarrhyth-
mia decreased during carvedilol loading and increased after
carvedilol withdrawal.
† Carvedilol impacted the SGNA–VNA correlation and circar-
dian patterns.
† After thedevelopmentof persistent atrial fibrillation (AF), car-
vedilol administration did not suppress SGNA, VNA, and
SLGPNA,while carvedilol withdrawal during AFwas followed
by increased SGNA.
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by 19% [from 0.9 mV/s (95% CI, 0.8–1.0) to 0.7 mV/s (95% CI, 0.6–
0.8), P, 0.001], and SLGPNA by 12% [from 3.8 mV/s (95%CI, 3.0–
4.5) to3.3 mV/s (95%CI, 2.6–4.0), P ¼ 0.005, Figure 2]. Furthermore,
these effects persisted for up to 3 days after carvedilol withdrawal.
On Day 3 after withdrawal, SGNA was reduced by 16% [from
2.4 mV/s (95% CI, 2.2–2.6) to 2.1 mV/s (95% CI, 1.9–2.2), P,
0.001], VNA by 29% [from 0.9 mV/s (95% CI, 0.8–1.0) to 0.6 mV/s
(95% CI, 0.6–0.7), P, 0.001], and SLGPNA by 19% [from 3.8 mV/s
(95% CI, 3.0–4.5) to 3.0 mV/s (95% CI, 2.4–3.7), P, 0.001] com-
pared with the baseline. As shown in Figure 2, there was a significant
reduction in SGNA at 8 AM during and after carvedilol loading com-
pared with the baseline.
Carvedilol suppresses vagal nerve activity
Twodogs in the phase 1 study showed significant changes in SGNA–
VNA correlation during carvedilol loading (Figure 3). Figure 3A shows
the effects of carvedilol on the SGNA–VNA and VNA–SLGPNA
correlations. In this example, the baseline SGNA–VNA correlation
was L-shaped, but the lower arm of the ‘L’ disappeared on Days 5–6
(between the first two arrows), and reappeared after carvedilolwith-
drawal. Actual nerve activity recorded before and during carvedilol
loading is seen in Figure 3B and C. Figure 3C show the suppression of
VNA and SLGPNA by carvedilol in comparison with Figure 3B. This
finding indicates a highly selective suppression of VNA by carvedilol
in this dog. The SGNA–VNA correlation coefficient was reduced at
the end of carvedilol loading and just after carvedilol withdrawal
(from 0.443 to 20.079), but recovered to its baseline value 3 days
after carvedilol withdrawal. While the VNA–SLGPNA correlation
coefficient did not change significantly during carvedilol loading, sig-
nificant suppression of VNAwas observed. The arrowheads point to
the high VNA and SLGPNA portion of the graph. That portion was
suppressed after Day 4 and returned 3 days after carvedilol with-
drawal.
Circadian variations of carvedilol effects
Thecircadian variationof the SGNA–VNAcorrelationwas analysed.
The SGNA–VNA correlation increased during daytime and
decreasedduring night-time (Figure 4A). Therewas a significant differ-
ence between the lowest correlation coefficient of SGNA–VNA
(8 PM to 12 AM) and the daytime coefficient (Figure 4C). However,
after carvedilol loading, this difference in the SGNA–VNA correl-
ation coefficientwas attenuated, resulting in the disappearanceof sig-
nificant circadian variation (Figure 4B and D). Figure 4B shows a major
reduction in SGNA from8AM to 12 PM,which is consistentwith the
absence of circadian variation in Figure 4D.
Effect of carvedilol on paroxysmal atrial
tachyarrhythmia
We detected 226 episodes of PAT during 2088 h of pre-pacing
recording in eight dogs. Carvedilol loading significantly reduced
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Figure 1 Effects of carvedilol on heart rate. (A) Diagram of the study protocol. Two weeks after the operation, a carvedilol loading study was
performed during sinus rhythm. A rapid atrial pacing protocol was then initiated and maintained until the development of persistent (.48 h) AF.
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the incidence of PAT [7.9/day (95% CI, 2.8–13.0) vs. 2.5/day (95%
CI, 1.8–3.2), P, 0.001, Figure 5A]. After withdrawal of carvedilol,
the number of PAT episodes increased [from 2.5/day (95% CI,
1.8–3.2] to 5.0/day (95% CI, 2.4–7.6), P ¼ 0.002]. The number of
PAT episodes decreased significantly between carvedilol loading
Days 2 and 7 (Figure 5B). In addition, the duration of PAT decreased
significantly after carvedilol loading [67.5 s/day (95% CI, 8.2–126.8)
vs. 16.5 s/day (95% CI, 10.3–22.8), P ¼ 0.003], and increased
after carvedilol withdrawal [16.5 s/day (95% CI, 10.3–22.8) vs.
36.9 s/day (95% CI, 8.9–62.8), P ¼ 0.162, Figure 5C]. Figure 5D
shows a significant reduction in PAT duration between carvedilol
loading Days 2 and 7.
Carvedilol converts persistent atrial
fibrillation to sinus rhythm
Three of the eight dogswith persistent AF converted to sinus rhythm
during carvedilol loading. Atrial fibrillation was converted to sinus
rhythm after 2, 4, and 6 days of carvedilol loading, respectively.
There were no significant changes in SGNA [2.2 mV/s (95% CI,
1.9–2.5) in AF vs. 2.1 mV/s (95% CI, 1.9–2.4) during carvedilol
loading vs. 2.2 mV/s (95% CI, 1.9–2.5) after sinus conversion, all
P. 0.05]. Vagal nerve activity tended to increase during carvedilol
loading and after sinus conversion, but the changes were statistically
insignificant [0.9 mV/s (95% CI, 0.8–1.1) in AF vs. 1.0 mV/s (95% CI,
6
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0.9–1.1) during carvedilol loading vs. 1.0 mV/s (95% CI, 0.9–1.1)
after conversion to sinus rhythm, all P . 0.05].
Carvedilol had effects on nerve activity or
heart rate during persistent atrial
fibrillation
Carvedilol did not suppress Int-NA in the five dogs that did not
convert to sinus rhythm during the loading period. No significant
changes were observed in SGNA [from 2.3 mV/s (95% CI, 2.1–2.5)
to 2.4 mV/s (95% CI, 2.2–2.6)], VNA [from 0.8 mV/s (95% CI, 0.8–
0.8) to 0.8 mV/s (95% CI, 0.8–0.8), or SLGPNA [from 17.0 mV/s
(95%CI, 15.6–18.5) to 16.9 mV/s (95%CI, 15.6–18.3)] during carve-
dilol loading (all P . 0.05, Figure 6). However, after carvedilol with-
drawal, SGNA increased by 16% [from 2.4 mV/s (95% CI, 2.2–2.6)
to 2.7 mV/s (95% CI, 2.6–3.0), P ¼ 0.027], whereas VNA and
SLGPNA remained unchanged [VNA from 0.8 mV/s (95% CI, 0.8–
0.8) to 0.9 mV/s (95% CI, 0.8–0.9); SLGPNA from 16.9 mV/s (95%
CI, 15.6–18.3) to 18.4 mV/s (95% CI, 17.3–19.6), P. 0.05]. After
thedevelopmentofpersistentAF, the averageheart ratewas increased
from 102.8 b.p.m. (95% CI, 100.4–105.2) to 123.3 b.p.m. (95% CI,
121.5–125.0) (P, 0.05).Carvedilol significantlyreducedtheventricu-
lar rate [from123.3 b.p.m. (95%CI, 121.5–125.0) to120.3 b.p.m. (95%
CI, 119.5–121.2), P, 0.001]. Furthermore, ventricular rate was also
reduced after carvedilol withdrawal [123.3 b.p.m. (95% CI, 121.5–
125.0) vs. 120.2 b.p.m. (95% CI, 119.0–121.5), P, 0.001 compared
with before carvedilol loading]. Prior to carvedilol loading, the ven-
tricular response rate during AF was higher from 8 AM to 4 PM
(124.7+11.4 b.p.m.) than from midnight to 8 AM (120.3+
5.6 b.p.m., P ¼ 0.025). However, this daytime heart rate elevation
was not significantly affected by carvedilol loading or withdrawal.
Discussion
This study demonstrated that (i) at baseline, carvedilol effectively
suppressed SGNA, VNA, SLGPNA, heart rate, and spontaneous
PAT episodes; (ii) carvedilol had an effect on the SGNA–VNA cor-
relation and circardian patterns; and (iii) during AF, carvedilol admin-
istration did not suppress ANA, but carvedilol withdrawal was
followed by increased ANA.
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Effects of carvedilol on cardiac ANAs during sinus rhythm and AF 1087
by guest on Decem
ber 22, 2016
D
ow
nloaded from
 
Neural modulation by carvedilol
Carvedilol is known to have multiple actions. By affecting a variety of
ion channels and currents, it exerts a more potent antiarrhythmic
effect than those exerted by other b-blocking agents. Carvedilol is
a potent blocker of the Ca2+ channels, Na+ channels, and various
native K+ channels, that is the rapidly activating component of the
delayed rectifier K+ current (Ikr), the transient outward K
+ current
(Ito), and the slowly activating component of the delayed rectifier
K+ current (Iks).
12,13 Sympathetic nerve activity is known to be im-
portant in cardiac arrhythmogenesis and sudden death.14 Therefore,
drugs actingon thenervous systemmayhaveantiarrhythmic and anti-
fibrillatory properties that potentially provide a therapeutic ap-
proach to the prevention of sudden cardiac death.15 A major
finding of the present study is that carvedilol suppressed ANA
outflow in ambulatory dogs during sinus rhythm. We also demon-
strated that carvedilol suppressed the baseline heart rate and
reduced the numberof PATepisodes, consistentwith the hypothesis
that reduction of sympathetic outflow is an effective therapeutic ap-
proach to cardiac arrhythmia. Our finding is consistent with a clinical
study that showed carvedilol reduces systemic and cardiac norepin-
ephrine spillover, an indirect measure of norepinephrine release.7
The authors of the latter manuscript attributed their findings to the
blocking effect of carvedilol on pre-junctional b2-adrenergic recep-
tors that are responsible for the release of norepinephrine from
the nerve terminals. However, a more recent finding showed that
carvedilol is the only b-blocker that directly reduces the open dur-
ation of the cardiac ryanodine receptor.16 Because there is a tight
functional coupling between ryanodine receptors and L-type
calcium channels in the neurons,17 it is possible that the ryanodine
receptor-suppressing effects of carvedilol contributed to the
reduced ANA discharges observed in the present study.
Vagus nerves are mainly composed of choline acetyltransferase
positive-cholinergic nerves, but a small portion of the nerves
stained positively for thyroxine hydroxylase.18 Vagal nerve activity
may include sympathetic andparasympathetic nerveactivities. In add-
ition, adrenergic and cholinergic nerves are distributed in the pul-
monary vein (PV) and LA junction,19 suggesting that SLGPNA may
include both nerve activities. Therefore, the effects of carvedilol
are not specific to SGNA, as VNA and SLGPNA are also suppressed
during carvedilol loading. Because simultaneous sympathovagal dis-
charges and SLGPNA discharges are known to trigger PAT in this
model,8,20,21 simultaneous reduction of ANA outflow from all
these structures may in part underlie the antiarrhythmic efficacy of
carvedilol.
Carvedilol withdrawal in sinus rhythm
Abrupt b-blocker discontinuation has been reported to increase is-
chaemic events in patients with coronary heart disease.22,23 Heart
rate variability measurements indicate that b-blocker withdrawal in
congestive heart failure shifts the autonomic balance in favour of
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increased sympathetic tone.24However, there is no study thatdirect-
ly evaluated the change of cardiac ANAs afterb-blocker withdrawal.
A secondmajor finding of this study is that there is no ANA rebound
after carvedilol withdrawal in sinus rhythm, whereas significant
rebound was observed after carvedilol withdrawal during persistent
AF. There is significant neural remodelling, including nerve sprouting
and atrial sympathetic hyperinnervation, in canine models of
pacing-induced AF and in patients with AF.21,25 The anatomical evi-
dence of cardiac nerve sprouting, coupled with increased SGNA
and VNA,8 contribute to the spontaneous PAT in this canine
model. However, in addition to suppressing sympathetic outflow,
carvedilol also suppresses cardiac b-receptors. The effects of carve-
dilol on ANA outflow and on themyocardiummay not be parallel to
each other. Therefore, carvedilol withdrawal during sinus rhythm is
associated with a further reduction of ANA but a rebound increase
of PAT episodes.
Neural modulation for atrial fibrillation
Neural modulation has been used by multiple authors to control AF.
Fat pads were innervated by sympathetic and parasympathetic nerve
fibres.19 Radiofrequency catheter ablation aimed at the ganlionated
plexi in the fat pad may reduce AF recurrence in human patients.26
Ganglionated plexi ablation as an adjunt to PV isolation showed com-
parable results with standard PV isolation.27 Oh et al.28 recently
reported that botulinum toxin injection into fat pads temporarily
blocked autonomic activity, resulting in the suppression of vagally
mediated AF. However, the invasiveness of botox injection and the
short period of its effect may limit its application in AF patients. Yu
et al.29 reported a novel drug delivery method using magnetic nano-
particles targeting fat pads. An intravascular drug delivery system
combined with a magnetic field could be used to target epicardial
fat pads. However, because it is difficult to eliminate fat pads com-
pletely by any method, the above techniques may lead to only
partial denervation and increased vulnerability to vagally induced
AF.30 Similarly, dissection of a single fat pad may paradoxically in-
crease the incidenceof post-operativeAF.31 Therefore, drugs that ef-
fectively suppress sympathetic outflow hold significant promise in
treatment of AF.
Study limitations
Because threeof theeight dogs converted to sinus rhythmduring car-
vedilol loading, the data on AF are limited to the animals that failed to
convert. The mechanism of AF termination during carvedilol loading
remains unclear. Our study did not compare the effects of carvedilol
on ANA with those of other b-blockers. Therefore, it cannot con-
clude whether the observed autonomic modulation effects are spe-
cific to carvedilol or represent class effects.
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Figure5 Incidence and duration of PAT before (PRE), during (CVD), and after (POST) carvedilol loading. Carvedilol loading significantly reduced
the incidence (A, B) and duration (C,D) of PAT betweenDays 2 and 7. After withdrawal of carvedilol, the incidence and duration of PAT returned to
baseline level. *P, 0.05 vs. PRE.
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Conclusions
This studydemonstrates that carvedilol suppressesANAduring sinus
rhythm but not during AF. Carvedilol withdrawal is associated with
continued ANA suppression in sinus rhythm, but with ANA
rebound in AF. These findings suggest that b-blockers can directly
suppress ANA in ambulatory dogs during sinus rhythm, and that
the ANA response to b-blockers is altered by the induction of AF.
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Repetitive non-reentrant ventriculoatrial synchrony: a rare cause
of overestimating atrial fibrillation burden
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Device interrogation of an asymptomatic pace-
maker recipient (St JudeMedical AccentDR) fol-
lowing ablation of atrial fibrillation (AF), revealed
29 auto mode switch (AMS) episodes,
thus raising the suspicion of asymptomatic AF
recurrences. However, all stored AMS episodes
were due to repetitive non-reentrant ventricu-
loatrial synchrony (RNRVAS).
In St Jude Medical devices, AMS activation is
based on the calculation of the filtered atrial
rate interval (FARI), a running interval calculated
beatbybeat. Bothpaced and sensed atrial events,
including those fallingwithin the post-ventricular
atrial refractory period (PVARP), are used for
FARI calculation. Auto mode switch occurs
when FARI is less than the programmed atrial
tachycardia detection interval (ATDI) and an
atrial sensed (but not refractory) event is
recorded. In our case, the sequence of atrial
events in the RNRVAS resulted in FARI shortening below the ATDI. When an atrial event was sensed beyond the abbreviated, due to
rate-dependency, PVARP, then AMS was triggered (Figure, SIR: sensor indicated rate).
Repetitive non-reentrant ventriculoatrial synchrony can be prevented by avoiding device programming that results in short atrial escape
intervals, which is usually the case when prolonged atrioventricular delay is combined with rapid, sensor-driven, atrial pacing rates.
In conclusion, RNRVAS may result in pseudo mode switch, thus impairing accurate assessment of subclinical atrial tachyarrhythmias.
Given the increased stroke risk associated with subclinical atrial tachyarrhythmias, careful evaluation of electrograms is essential to ascer-
tain the true cause of AMS and avoid false estimation of AF burden.
The full-length version of this report can be viewed at: http://www.escardio.org/communities/EHRA/publications/ep-case-reports/
Documents/repetitive-non-reentrant-ventriculoatrial-synchrony.pdf.
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